CLINICAL RESEARCH: HEART FAILURE
Predictors of late development of heart failure in stable survivors of myocardial infarction
The CARE study
Eldrin F. Lewis, MD, MPH*,
Lemuel A. Moye, MD, PhD ,
Jean L. Rouleau, MD, FACC ,
Frank M. Sacks, MD*,
J. Malcolm O. Arnold, MD, FACC ,
J. Wayne Warnica, MD, FACC||,
Greg C. Flaker, MD, FACC¶,
Eugene Braunwald, MD, FACC* and
Marc A. Pfeffer, MD, PhD, FACC*,*
* Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
University of Texas School of Public Health, Houston, Texas, USA
University of Toronto, Toronto, Ontario, Canada
London Health Sciences Center, London, Ontario, Canada
|| Foothills Hospital, Calgary, Alberta, Canada
¶ University of Missouri Hospital and Clinics, Columbia, Missouri, USA
Manuscript received March 3, 2003;
revised manuscript received April 29, 2003,
accepted May 9, 2003.
* Reprint requests and correspondence: Dr. Marc A. Pfeffer, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115, USA.
mpfeffer{at}rics.bwh.harvard.edu
OBJECTIVES: We sought to determine the predictors of heart failure (HF) development in long-term survivors of myocardial infarction (MI).
BACKGROUND: Modern strategies of acute MI care have resulted in an increasing proportion of survivors at heightened risk of future non-fatal events, including HF.
METHODS: We assessed the risk of developing HF in 3,860 stable MI patients without a previous history of HF, who were enrolled in the Cholesterol And Recurrent Events (CARE) trial a median of 10 months post MI. Baseline characteristics of patients who did or did not develop HF during the five years of observation were assessed.
RESULTS: A total of 243 patients (6.3%) developed HF in a linear pattern at a rate of 1.3%/year. Heart failure development markedly increased the risk of death (hazard ratio 10.2, 95% confidence interval 7.7 to 13.5). Fifty-seven patients (23.5%) who developed HF had a recurrent MI between enrollment and the onset of HF, increasing the risk fivefold. The most important predictors of HF were age and left ventricular ejection fraction. Other predictors included diabetes, history of hypertension, previous MI, and baseline heart rate. Moderate exercise three or more times per week was independently associated with a 30% lower risk of HF.
CONCLUSIONS: Heart failure post MI occurs in a time-dependent fashion, which is usually not a direct consequence of a detectable interim MI. Patients who experience late-onset HF have a 10-fold increased risk of death compared with other MI survivors. Baseline characteristics can risk stratify patients at high risk of subsequent HF.
|
Abbreviations and Acronyms
| | CARE | = Cholesterol And Recurrent Events trial | | HF | = heart failure | | HR | = hazard ratio | | LVEF | = left ventricular ejection fraction | | MI | = myocardial infarction | | SAVE | = Survival And Ventricular Enlargement trial |
|
This article has been cited by other articles:
|
|
|
|
 
R. S. Velagaleti, M. J. Pencina, J. M. Murabito, T. J. Wang, N. I. Parikh, R. B. D'Agostino, D. Levy, W. B. Kannel, and R. S. Vasan
Long-Term Trends in the Incidence of Heart Failure After Myocardial Infarction
Circulation,
November 11, 2008;
118(20):
2057 - 2062.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Riad, S. Jager, M. Sobirey, F. Escher, A. Yaulema-Riss, D. Westermann, A. Karatas, M. M. Heimesaat, S. Bereswill, D. Dragun, et al.
Toll-Like Receptor-4 Modulates Survival by Induction of Left Ventricular Remodeling after Myocardial Infarction in Mice
J. Immunol.,
May 15, 2008;
180(10):
6954 - 6961.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. F. Lewis, E. J. Velazquez, S. D. Solomon, A. S. Hellkamp, J. J.V. McMurray, J. Mathias, J.-L. Rouleau, A. P. Maggioni, K. Swedberg, L. Kober, et al.
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study
Eur. Heart J.,
March 2, 2008;
29(6):
748 - 756.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Timmers, J. P.G. Sluijter, J. K. van Keulen, I. E. Hoefer, M. G.J. Nederhoff, M.-J. Goumans, P. A. Doevendans, C. J.A. van Echteld, J. A. Joles, P. H. Quax, et al.
Toll-Like Receptor 4 Mediates Maladaptive Left Ventricular Remodeling and Impairs Cardiac Function After Myocardial Infarction
Circ. Res.,
February 1, 2008;
102(2):
257 - 264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Thune, J. Signorovitch, L. Kober, E. J. Velazquez, J. J.V. McMurray, R. M. Califf, A. P. Maggioni, J. L. Rouleau, J. Howlett, S. Zelenkofske, et al.
Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction
Hypertension,
January 1, 2008;
51(1):
48 - 54.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Aronson, M. Suleiman, Y. Agmon, A. Suleiman, M. Blich, M. Kapeliovich, R. Beyar, W. Markiewicz, and H. Hammerman
Changes in haemoglobin levels during hospital course and long-term outcome after acute myocardial infarction
Eur. Heart J.,
June 1, 2007;
28(11):
1289 - 1296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Timmers, J. P.G. Sluijter, C. W.J. Verlaan, P. Steendijk, M. J. Cramer, M. Emons, C. Strijder, P. F. Grundeman, S. K. Sze, L. Hua, et al.
Cyclooxygenase-2 Inhibition Increases Mortality, Enhances Left Ventricular Remodeling, and Impairs Systolic Function After Myocardial Infarction in the Pig
Circulation,
January 23, 2007;
115(3):
326 - 332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Aronson, N. Goldsher, R. Zukermann, M. Kapeliovich, J. Lessick, D. Mutlak, S. Dabbah, W. Markiewicz, R. Beyar, H. Hammerman, et al.
Ischemic Mitral Regurgitation and Risk of Heart Failure After Myocardial Infarction
Arch Intern Med,
November 27, 2006;
166(21):
2362 - 2368.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Ernens, D. Rouy, E. Velot, Y. Devaux, and D. R. Wagner
Adenosine Inhibits Matrix Metalloproteinase-9 Secretion By Neutrophils: Implication of A2a Receptor and cAMP/PKA/Ca2+ Pathway
Circ. Res.,
September 15, 2006;
99(6):
590 - 597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Scirica, D. A. Morrow, C. P. Cannon, K. K. Ray, M. S. Sabatine, P. Jarolim, A. Shui, C. H. McCabe, E. Braunwald, and for the PROVE IT-TIMI 22 Investigators
Intensive Statin Therapy and the Risk of Hospitalization for Heart Failure After an Acute Coronary Syndrome in the PROVE IT-TIMI 22 Study
J. Am. Coll. Cardiol.,
June 6, 2006;
47(11):
2326 - 2331.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Goldberg, H. Hammerman, S. Petcherski, M. Nassar, A. Zdorovyak, S. Yalonetsky, M. Kapeliovich, Y. Agmon, R. Beyar, W. Markiewicz, et al.
Hyponatremia and Long-term Mortality in Survivors of Acute ST-Elevation Myocardial Infarction.
Arch Intern Med,
April 10, 2006;
166(7):
781 - 786.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Suleiman, R. Khatib, Y. Agmon, R. Mahamid, M. Boulos, M. Kapeliovich, Y. Levy, R. Beyar, W. Markiewicz, H. Hammerman, et al.
Early Inflammation and Risk of Long-Term Development of Heart Failure and Mortality in Survivors of Acute Myocardial Infarction: Predictive Role of C-Reactive Protein
J. Am. Coll. Cardiol.,
March 7, 2006;
47(5):
962 - 968.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. D. White, P. E.G. Aylward, Z. Huang, A. J. Dalby, W. D. Weaver, S. Barvik, J. A. Marin-Neto, J. Murin, R. O. Nordlander, W. H. van Gilst, et al.
Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction: Results From the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Circulation,
November 29, 2005;
112(22):
3391 - 3399.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Authors/Task Force Members, K. Swedberg, Writing Committee:, J. Cleland, H. Dargie, H. Drexler, F. Follath, M. Komajda, L. Tavazzi, O. A. Smiseth, et al.
Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology
Eur. Heart J.,
June 1, 2005;
26(11):
1115 - 1140.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Valgimigli, C. Ceconi, P. Malagutti, E. Merli, O. Soukhomovskaia, G. Francolini, G. Cicchitelli, A. Olivares, G. Parrinello, G. Percoco, et al.
Tumor Necrosis Factor-{alpha} Receptor 1 Is a Major Predictor of Mortality and New-Onset Heart Failure in Patients With Acute Myocardial Infarction: The Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) Study
Circulation,
February 22, 2005;
111(7):
863 - 870.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. T. Bloomgarden
Inpatient Diabetes Control: Rationale
Diabetes Care,
August 1, 2004;
27(8):
2074 - 2080.
[Full Text]
[PDF]
|
|
|
|
